Literature DB >> 33632380

Demedicalisation of HIV interventions to end HIV in the Asia-Pacific.

Rena Janamnuaysook1, Kimberly Elizabeth Green2, Pich Seekaew3, Bao Ngoc Vu2, Huu Van Ngo2, Hong Anh Doan2, Supabhorn Pengnonyang4, Ravipa Vannakit5, Praphan Phanuphak4, Nittaya Phanuphak6, Reshmie Ashmanie Ramautarsing4.   

Abstract

Despite the challenges to the HIV response in the Asia-Pacific, a demedicalisation of HIV intervention has been demonstrated to be an important strategy to maximise the uptake of HIV prevention tools among key populations in this region. Demedicalisation of HIV interventions translates medical discourse and shifts the paradigm from a disease-focused to a people-centred approach. It also recognises real-life experiences of key populations in the HIV response by empowering them to voice their needs and be at the forefront of the epidemic control. We further categorise a demedicalisation approach into three frameworks: (1) the demystification of clinical or medical concerns; (2) the destigmatisation of people living with HIV; and (3) the decentralisation of healthcare services. This article reviewed the demedicalisation framework by looking at the HIV intervention examples from countries in the Asia-Pacific, which included: (1) a study on drug-drug interaction between pre-exposure prophylaxis and feminising hormone treatment for transgender women; (2) the roles of key population-led health services; and (3) certification of key population lay providers.

Entities:  

Mesh:

Year:  2021        PMID: 33632380     DOI: 10.1071/SH20172

Source DB:  PubMed          Journal:  Sex Health        ISSN: 1448-5028            Impact factor:   2.706


  4 in total

1.  Cost-effectiveness and impact of pre-exposure prophylaxis to prevent HIV among men who have sex with men in Asia: A modelling study.

Authors:  Debra C Ten Brink; Rowan Martin-Hughes; Mark E Minnery; Aaron J Osborne; Heather-Marie A Schmidt; Shona Dalal; Kimberly E Green; Reshmie Ramaurtarsing; David P Wilson; Sherrie L Kelly
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

2.  Epidemiological Characteristics and Transmissibility of Human Immunodeficiency Virus in Nanning City, China, 2001-2020.

Authors:  Qian Lin; Bin Deng; Jia Rui; Song-Bai Guo; Qingqing Hu; Qiuping Chen; Chi Tang; Lina Zhou; Zeyu Zhao; Shengnan Lin; Yuanzhao Zhu; Meng Yang; Yao Wang; Jingwen Xu; Xingchun Liu; Tianlong Yang; Peihua Li; Zhuoyang Li; Li Luo; Weikang Liu; Chan Liu; Jiefeng Huang; Min Yao; Mengni Nong; Liping Nong; Jinglan Wu; Na Luo; Shihai Chen; Roger Frutos; Shixiong Yang; Qun Li; Jing-An Cui; Tianmu Chen
Journal:  Front Public Health       Date:  2021-12-14

3.  HIV Pre-exposure Prophylaxis Uptake and Continuation Among Key Populations in Cameroon: Lessons Learned From the CHAMP Program.

Authors:  Jackson Jr Nforbewing Ndenkeh; Anna L Bowring; Iliassou Mfochive Njindam; Romeo Dongfack Folem; Guy Christian Hendji Fako; Florent Gnintedem Ngueguim; Oscar Leyou Gayou; Kelly Lepawa; Christine Minka Minka; Christine Manyo Batoum; Sandra Georges; Edith Temgoua; Valery Nzima; David Anouar Kob; Zacheus Zeh Akiy; William Philbrick; Daniel Levitt; Dora Curry; Stefan Baral
Journal:  J Acquir Immune Defic Syndr       Date:  2022-05-10       Impact factor: 3.771

4.  Caring for the whole person: transgender-competent HIV pre-exposure prophylaxis as part of integrated primary healthcare services in Vietnam.

Authors:  Anh H Doan; Chau M H Vu; Thu T Nguyen; Kimberly E Green; Huong T T Phan; Rena Janamnuaysook; Bao N Vu; Thanh M Le; Khang Q Do; Tham T Tran; Trang M Ngo; Lopa Basu; Long K Tran; Zoe Humeau
Journal:  J Int AIDS Soc       Date:  2022-10       Impact factor: 6.707

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.